These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


349 related items for PubMed ID: 19622887

  • 1. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.
    Petri S, Tölle T, Straube A, Pfaffenrath V, Stefenelli U, Ceballos-Baumann A, Dysport Migraine Study Group.
    Eur Neurol; 2009; 62(4):204-11. PubMed ID: 19622887
    [Abstract] [Full Text] [Related]

  • 2. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR.
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
    Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A.
    Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314
    [Abstract] [Full Text] [Related]

  • 7. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW.
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [Abstract] [Full Text] [Related]

  • 8. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group.
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
    Vo AH, Satori R, Jabbari B, Green J, Killgore WD, Labutta R, Campbell WW.
    Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312
    [Abstract] [Full Text] [Related]

  • 10. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
    Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group.
    Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
    Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP, Study Group.
    Headache; 2009 Feb; 49(2):216-26. PubMed ID: 19222595
    [Abstract] [Full Text] [Related]

  • 12. Botulinum toxin type A in prophylactic treatment of migraine.
    Anand KS, Prasad A, Singh MM, Sharma S, Bala K.
    Am J Ther; 2006 Feb; 13(3):183-7. PubMed ID: 16772757
    [Abstract] [Full Text] [Related]

  • 13. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
    Freitag FG, Diamond S, Diamond M, Urban G.
    Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
    Göbel H, Heinze A, Reichel G, Hefter H, Benecke R, Dysport myofascial pain study group.
    Pain; 2006 Nov; 125(1-2):82-8. PubMed ID: 16750294
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
    Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL.
    Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
    [Abstract] [Full Text] [Related]

  • 16. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial.
    Singh JA, Mahowald ML, Noorbaloochi S.
    Transl Res; 2009 May; 153(5):205-16. PubMed ID: 19375681
    [Abstract] [Full Text] [Related]

  • 17. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study.
    Schulte-Mattler WJ, Krack P, BoNTTH Study Group.
    Pain; 2004 May; 109(1-2):110-4. PubMed ID: 15082132
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
    Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG, Tonabersat TON-01-05 Study Group.
    Cephalalgia; 2009 Jul; 29(7):742-50. PubMed ID: 19222510
    [Abstract] [Full Text] [Related]

  • 19. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY, North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group.
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [Abstract] [Full Text] [Related]

  • 20. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?
    Schellenberg R, Lichtenthal A, Wöhling H, Graf C, Brixius K.
    Headache; 2008 Jan; 48(1):118-25. PubMed ID: 18184294
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.